Frazier Life Sciences Management’s Immunovant IMVT Stock Holding History

Frazier Life Sciences Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-300,000	Closed	-$5.69M	–	53
2023 Q2	$5.69M	Sell	300,000 -285,759	-49%	-$5.33M	0.34%	39
2023 Q1	$9.09M	Hold	585,759	–	–	0.66%	31
2022 Q4	$10.4M	Hold	585,759	–	–	0.65%	30
2022 Q3	$3.27M	Hold	585,759	–	–	0.25%	37
2022 Q2	$2.28M	Hold	585,759	–	–	0.22%	35
2022 Q1	$3.23M	Buy	+585,759	New	+$3.65M	0.28%	38

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Frazier Life Sciences Management's IMVT Position: Q3 2023 in Review

Frazier Life Sciences Management sold out of Immunovant (IMVT) in Q3 2023, closing a stake of 300,000 shares — an estimated $5.69M sold.

Frazier Life Sciences Management first reported a position in IMVT in Q1 2022 and held it in 6 quarters. The position peaked at $10.4M in Q4 2022. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2023.

Frazier Life Sciences Management reported no remaining Immunovant position as of Q3 2023 after selling out during the quarter.
Frazier Life Sciences Management sold 300,000 Immunovant shares in Q3 2023, an estimated $5.69M.
Frazier Life Sciences Management first reported a position in Immunovant in Q1 2022 and held it in 6 quarters.
Frazier Life Sciences Management's Immunovant position peaked at $10.4M in Q4 2022.
181 funds tracked by Wall St. Rank held Immunovant as of Q3 2023.

Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.